|1.||Bobyntsev, I I: 1 article (01/2005)|
|2.||Severyanova, L A: 1 article (01/2005)|
|3.||Dolzhikov, A A: 1 article (01/2005)|
|1.||Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
01/01/1992 - "Therapeutic efficacy of surfagon, an analog of LH-RH which was injected subcutaneously at a daily dose of 100 micrograms/kg for 30 days, was investigated in ACI male rats with induced prostatic adenoma. "
01/01/1992 - "[Experimental approaches to treatment of prostatic adenoma with the luliberin analog surfagon]."
|2.||Follicular Cyst (Follicular Cysts)
11/01/1989 - "It is assumed that surfagon will be effective for the treatment of anovulatory condition and ovarian follicular cysts in women."
11/01/1989 - "The use of a synthetic peptide analog of LH-RH agonist--[D-Ala6, des Gly10, Pro9]-LH-RH ethylamide (surfagon) at microdoses and in short courses returned to normal the ovulatory cycle in the anovulatory condition in rats and caused luteinization of follicular cysts in rats and cows with further normalization of ovarian function. "
|4.||Ovarian Cysts (Ovarian Cyst)
|1.||Gonadotropin-Releasing Hormone (GnRH)